Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS
Michael E. Østergaard(Ionis Pharmaceuticals (United States)), Punit P. Seth(Ionis Pharmaceuticals (United States)), Erika B. Villanueva(University of British Columbia), Crystal N. Doty(University of British Columbia), Holly Kordasiewicz(Ionis Pharmaceuticals (United States)), Andrew T. Watt(University of British Columbia), Niels H. Skotte(University of British Columbia), Kuljeet Vaid(University of British Columbia), Amber L. Southwell(University of Central Florida), C. Frank Bennett(Pennsylvania State University), Michael R. Hayden(University of British Columbia), Eric E. Swayze(Ionis Pharmaceuticals (United States))
Cited by 162
Related Papers
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
Huntington disease
|Nature Reviews Disease Primers|2015|1.6k
Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
|Nature Genetics|2003|976